Non-targeted lipidomics of CSF and frontal cortex grey and white matter in control, mild cognitive impairment, and Alzheimer's disease subjects

Acta Neuropsychiatrica

Volumn 27, Issue 5, 2015, Pages 270-278

  Wood, Paul L ^a   Barnette, Brooke L ^a   Kaye, Jeffrey A ^b   Quinn, Joseph F ^b   Woltjer, Randall L ^b  

^a Lincoln Memorial University   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; diacylglycerols; frontal cortex; lipidomics; mild cognitive impairment

Indexed keywords

CERAMIDE; CHOLINE; DIACYLGLYCEROL; GLYCEROL; GLYCEROLIPID; INOSITOL; ISOPRENOID; MONOACYLGLYCEROL; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PLASMALOGEN; SERINE; VERY LONG CHAIN FATTY ACID; BIOLOGICAL MARKER; DOCOSAHEXAENOIC ACID; PHOSPHATIDAL ETHANOLAMINES;

ADULT; AGING; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN LEVEL; BRAIN REGION; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DEMENTIA; FEMALE; FRONTAL CORTEX; GRAY MATTER; HUMAN; LIPID BLOOD LEVEL; LIPIDOMICS; MALE; MILD COGNITIVE IMPAIRMENT; WHITE MATTER; AGE; AGED; BRAIN; CEREBROSPINAL FLUID; DIAGNOSIS; FRONTAL LOBE; METABOLISM; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOMARKERS; BRAIN; DEMENTIA; DIAGNOSIS; DIGLYCERIDES; DOCOSAHEXAENOIC ACIDS; FEMALE; FRONTAL LOBE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MILD COGNITIVE IMPAIRMENT; MONOGLYCERIDES; NEUROPSYCHOLOGICAL TESTS; PLASMALOGENS; WHITE MATTER;

EID: 84941261801     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1017/neu.2015.18     Document Type: Article

References (36)

1. KORCZYN AD. The amyloid cascade hypothesis. Alzheimers Dement 2008;4:176-178.
2. CASTELLO MA, SORIANO S. On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis. Ageing Res Rev 2013;13C:10-12.
3. FARLOW MR, BROSCH JR. Immunotherapy for Alzheimer's disease. Neurol Clin 2013;31:869-878.
4. SCHNEIDER JA, ARVANITAKIS Z, BANG W, BENNETT DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69:2197-2204.
5. GANGULI M, RODRIGUEZ E. Age, Alzheimer's disease, and the big picture. Int Psychogeriatr 2011;23:1531-1534.
6. ERTEN-LYONS D, WOLTJER R, KAYE J et al. Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology 2013;81:977-983.
7. MAAROUF CL, DAUGS ID, KOKJOHN TA et al. Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging. PLoS One 2011;6:e27291.
8. KRAMER PL, XU H, WOLTJER RL et al. Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study. Neurobiol Aging 2011;32:2113-2122.
9. JELLINGER KA. Alzheimer's changes in non-demented and demented patients. Acta Neuropathol 1995;89:112-113.
10. ERTEN-LYONS D, WOLTJER RL, DODGE H et al. Factors associated with resistance to dementia despite high Alzheimer disease pathology. Neurology 2009;72:354-360.
11. WOOD PL. Lipidomics of Alzheimer's disease: current status. Alzheimers Res Ther 2012;4:5.
12. GINSBERG L, RAFIQUE S, XUEREB JH, RAPOPORT SI, GERSHFELD NL. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Brain Res 1995;698:223-226.
13. HAN X, HOLTZMAN DM, MCKEEL DW JR. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem 2001;77:1168-1180.
14. KOU J, KOVACS GG, HÖFTBERGER R et al. Peroxisomal alterations in Alzheimer's disease. Acta Neuropathol 2011;122:271-283.
15. CHAN RB, OLIVEIRA TG, CORTES EP et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem 2012;287:2678-2688.
16. CUTLER RG, KELLY J, STORIE K et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Nat Acad Sci U.S.A 2004;101:2070-2075.
17. HAN X, HOLTZMAN DM, MCKEEL DW JR., KELLEY J, MORRIS JC. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem 2002;82:809-818.
18. SCHUHMANN K, ALMEIDA R, BAUMERT M, HERZOG R, BORNSTEIN SR, SHEVCHENKO A. Shotgun lipidomics on a LTQ Orbitrap mass spectrometer by successive switching between acquisition polarity modes. J Mass Spectrom 2012;47:96-104.
19. WOOD PL, SHIRLEY NR. Lipidomics analysis of postmortem interval: preliminary evaluation of human skeletal muscle. Metabolomics 2013;3:3.
20. WOOD PL, FILIOU MD, OTTE DM, ZIMMER A, TURCK CW. Lipidomics reveals dysfunctional glycosynapses in schizophrenia and the G72/G30 transgenic mouse. Schizophrenia Res 2014;159:365-369.
21. CHENG H, WANG M, LI JL, CAIRNS NJ, HAN X. Specific changes of sulfatide levels in individuals with pre-clinical Alzheimer's disease: an early event in disease pathogenesis. J Neurochem 2013;127:733-738.
22. SHIMOHAMA S, SASAKI Y, FUJIMOTO S et al. Phospholipase C isozymes in the human brain and their changes in Alzheimer's disease. Neuroscience 1998;82:999-1007.
23. ZHANG D, DHILLON H, PRASAD MR, MARKESBERY WR. Regional levels of brain phospholipase Cgamma in Alzheimer's disease. Brain Res 1998;811:161-165.
24. WOOD PL, PHILLIPPS A, WOLTJER RL, KAYE JA, QUINN JF. Increased lysophosphatidylethanolamine and diacylglycerol levels in Alzheimer's disease plasma. JSM Alzheimer's Dis Relat Demen 2014;1:1001.
25. GONZÁLEZ-DOMÍNGUEZ R, GARCÍA-BARRERA T, GÓMEZ-ARIZA JL. Application of a novel metabolomic approach based on atmospheric pressure photoionization mass spectrometry using flow injection analysis for the study of Alzheimer's disease. Talanta 2015;131:480-489.
26. CARRASCO S, MÉRIDA I. Diacylglycerol, when simplicity becomes complex. Trends Biochem Sci 2007;32:27-36.
27. FAROOQUI AA, LISS L, HORROCKS LA. Stimulation of lipolytic enzymes in Alzheimer's disease. Ann Neurol 1988;23:306-308.
28. MULDER J, ZILBERTER M, PASQUARÉ SJ et al. Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain 2011;134:1041-1060.
29. GULYAS AI, CRAVATT BF, BRACEY MH et al. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci 2004;20:441-458.
30. SAVINAINEN JR, SAARIO SM, LAITINEN JT. The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta Physiol (Oxf) 2012;204:267-276.
31. PAULA-LIMA AC, BRITO-MOREIRA J, FERREIRA ST. Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease. J Neurochem 2013;126:191-202.
32. WOOD PL. Alzheimer's disease: status of the neuroinflammatory hypothesis. Curr Res Alzheimer's Dis 1998;3:1-8.
33. ANDERSON CM, STAHL A. SLC27 fatty acid transport proteins. Mol Aspects Med 2013;34:516-528.
34. QUINN JF, RAMAN R, THOMAS RG et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 2010;304:1903-1911.
35. BJORKLUND NL, REESE LC, SADAGOPARAMANUJAM VM, GHIRARDI V, WOLTJER RL, TAGLIALATELA G. Absence of amyloid β oligomers at the postsynapse and regulated synaptic Zn2+ in cognitively intact aged individuals with Alzheimer's disease neuropathology. Mol Neurodegener 2012;7:23.
36. WOOD PL, WOOD JA. Critical assessment of the status of Alzheimer's disease biomarkers. J Parkinson's Dis Alzheimer's Dis 2014;1:4.